Vaxart, Inc. (VXRT) 公布了其口服片剂新冠疫苗在2B期临床试验中,针对400名参与者组成的哨兵安全队列所收集的12个月顶线安全性数据。该数据旨在评估疫苗在中期随访期内的安全性与耐受性概况。
Vaxart, Inc. (VXRT) 公布了其口服片剂新冠疫苗在2B期临床试验中,针对400名参与者组成的哨兵安全队列所收集的12个月顶线安全性数据。该数据旨在评估疫苗在中期随访期内的安全性与耐受性概况。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.